Clinical trial
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed…
NCT00103376 · Medical University of South Carolina, Other · Terminated
Key facts
| NCT number | NCT00103376 |
|---|---|
| Title | Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer |
| Official title | VELCADE® (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer |
| Lead sponsor | Medical University of South Carolina, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Velcade, LH-RH Agonist, Androgen Receptor Antagonists |
| Enrollment | 23 |
| Start date | Oct 1, 2004 |
| Primary completion | Oct 1, 2009 |
| Completion | Jun 1, 2011 |
| First posted | Feb 8, 2005 |
| Last update posted | Nov 5, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: